TABLE 1 | Ongoing clinical trials of small-molecule inhibitors of the DNA damage response and related signalling pathways
From the following article:
DNA repair pathways as targets for cancer therapy
Thomas Helleday, Eva Petermann, Cecilia Lundin, Ben Hodgson & Ricky A. Sharma
Nature Reviews Cancer 8, 193-204 (March 2008)
doi:10.1038/nrc2342
| Agent (company) | Target molecule or pathway | Monotherapy or combination therapy agent(s) | Phase of clinical trial planned, ongoing or recently completed | Reference |
|---|---|---|---|---|
| AZD-2281 (Astra Zeneca) | PARP | Gemcitabine
Carboplatin Topotecan Monotherapy | Phase I
Phase I Phase I Phase II | http://www.astrazenecaclinicaltrials.com/article/525925.aspx |
| AG014699 (Pfizer) | PARP | Temozolomide antibody
Temozolomide | Phase I
Phase II | http://www.eddn.org/clinicalTr_caResUK.html |
| INO-1001 (Inotek) | PARP | Temozolomide | Phase I | http://www.inotekcorp.com/content/ino-1001.asp |
| BSI-201 (Bipar Sciences) | PARP | Monotherapy
Gemcitabine–carboplatin | Phase I
Phase II | http://www.biparsciences.com/BSI201.html |
| ABT-888 (Abbott Laboratories) | PARP | Temozolomide | Phase I | NCT00526617 |
| TRC-102 (Tracon Pharma) | BER | Temozolomide
Pemetrexed | Phase I
Phase I planned | http://www.traconpharma.com/content/pipeline_overview.html |
| Lomeguatrib (Astra Zeneca) | MGMT | Irinotecan
Temozolomide | Phase I
Phase II | http://www.astrazenecaclinicaltrials.com/article/525925.aspx |
| O6-Benzylguanine | MGMT | Temozolomide | Phase II | http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2006-C-0089.html |
| Decitabine (MGI Pharma121) | Hypermethylation of mismatch repair genes | Epirubicin, cisplatin, 5-fluorouracil
Carboplatin | Phase I
Phase II | http://pfsearch.ukcrn.org.uk/StudyDetail.aspx?TopicID=&StudyID=2192 |
| XL844 (Exilixis122) | CHK1, CHK2 | Gemcitabine | Phase I planned | http://www.exelixis.com/pipeline_xl844.shtml |
| The recent or current stage of development of clinical trials is indicated for individual compounds, which are grouped by molecular target. BER, base excision repair; CHK, checkpoint kinase; MGMT, O-6-methylguanine methyltransferase; PARP, poly(ADP-ribose) polymerase. | ||||
Download file
If the slide opens in your browser, select "File > Save As" to save it.